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Abstract
Background: Homocysteine and cysteine are considered as risk factors of cardiovascular disease. Homocysteine
influences the liver expression of ApoA-I and decreases its blood level and HDL in genetic mice model. We aimed
therefore to evaluate whether homocysteine and cysteine are associated with lipid parameters, and the joint
effects of them on the risk of coronary artery disease (CAD). Plasma total homocysteine (tHcy), cysteine (tCys) and
lipid markers were measured in 2058 consecutive coronary artery angiographic patients.
Results: Plasma tHcy but not tCys correlated negatively with ApoA-I (r = -0.153, P < 0.001) and with HDL
cholesterol (r = -0.148, P < 0.001), and correlated positively with the risk of CAD (OR: 1.61; 95% confidence interval;
1.26 to 2.05). Combination of high tHcy and high tCys levels was associated with decreased ApoA-I and HDL
cholesterol levels, and with increased risk of CAD (OR: 1.696, 95% CI (1.301-2.211)). Furthermore, low HDL
cholesterol combined with low tHcy or high tHcy all had increased risk for CAD (OR: 1.254, 95% CI (1.114-1.565);
OR: 1.332, 95% CI (1.093-1.624); respectively) whereas high HDL cholesterol counteracted the harmful effect of high
tHcy on the risk of CAD. However, only the combination of high tHcy and high ApoA-I had an increased risk for
CAD (OR: 1.438, 95% CI (1.170-1.768)).
Conclusions: The association of homocysteine and cysteine, ApoA-I or HDL cholesterol and their joint effects
provide new insights on its role on CAD.
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Introduction
Hyperhomocysteinemia has been considered as an inde-
pendent risk factor of coronary artery disease (CAD)
[1,2], but recent several large scale intervention studies
found lowering the plasma total homocysteine (tHcy)
with folic acid, vitamin B6 and B12 did not reduce the risk
of cardiovascular disease [3]. Thus the cause-effect rela-
tionship of homocysteine and cardiovascular disease is
controversial [4,5]. Furthermore, another sulf-containing
amino acid cysteine, structurally like to homocysteine,
was reported to be a risk factor of cardiovascular disease
[6-8], but in prospective study, plasma total cysteine
(tCys) was not an independent risk factor of cardiovascu-
lar disease [9]. The atherogenicity of homocysteine may
involve several mechanisms including LDL-cholesterol
oxidative modification, and HDL-cholesterol decrease
[10]. Several studies reported homocysteine inhibited
ApoA-I protein expression and decreased HDL choles-
terol levels in vitro and animal model [11,12]. Cysteine is
a vital structural and functional component of ApoB, the
protein of LDL [13,14]. Though less reactive than homo-
cysteine, cysteine exhibits autooxidation properties in the
presence of metal ions which can support superoxide-
mediated modification of LDL, thus facilitating foam cell
formation [15]. But the relationship between plasma
tHcy, tCys levels and lipid profiles in CAD patients are
still uncertain. Here, we investigated the relationship
between plasma tHcy, tCys and the lipid parameters, and
the joint effects of them on the risk of CAD.
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Subjects
The present cross-sectional study includes a total of 2,058
consecutive patients 40 to 85 years of age who had under-
gone a diagnostic coronary angiography at 3 hospitals
(Guangzhou Military General Hospital, Sun Yat-Sen
Memorial Hospital and Zhujiang Hospital) during Decem-
ber 2008 to September 2010 in Guangzhou, China. Those
with medical illnesses such as acute infection, chronic
hepatic dysfunction or nutritional derangements, malig-
nancies, and other severe medical illnesses were excluded.
All patients were free of drugs which would influence the
plasma homocysteine levels, including folate or multivita-
mins. Of the 2,058 patients, The CAD patients (n = 1053)
were defined as having significant stenosis in ≥ 1m a j o r
coronary artery and those (n = 1005) who did not have
significant stenosis of all arteries were defined as controls.
Any instances of concomitant illness and any current
medications were documented among our study subjects.
We recorded 209 cases (10%) with stroke, 108 individuals
(5.2%) with atrial fibrillation, 221 cases (10.6%) of arrhyth-
mia. The patients were accepted different medications that
were 59.7% subjects who used statins; 60.3% patients used
aspirin; 43% patients used beta-receptor blocker; 25%
patients used angiotensin-converting enzyme inhibitor;
20% subjects used nitrates. All patients were gave
informed consent to provide blood samples and the study
was approved by hospitals ethics committee.
Coronary angiography
Coronary angiographies were performed using a stan-
dard Judkins technique through the femoral artery or
brachial artery. The angiograms were interpreted by two
or more independent cardiologists in a blind fashion. All
evaluations were based on the American Heart Associa-
tion method [16]. CAD was defined as diameter stenosis
≥ 50% in the left main, left anterior descending, left cir-
cumflex, and/or right coronary artery.
Biochemical measurement
After the patients had fasted overnight, blood samples
were drawn into EDTA-containing tubes by venipunc-
ture. Samples were immediately placed on ice and trans-
ported to the laboratory. Plasma and serum were
prepared and stored at -80°C until analysis. The plasma
tHcy and tCys, which include the sum of protein-bound
and free homocysteine and cysteine, were simultaneously
measured by high-performance liquid chromatography
with fluorescence detection [17]. The total serum choles-
terol, triglyceride, and HDL cholesterol concentrations
were determined enzymatically. LDL cholesterol was
assayed using an indirect method. Apo A-I and ApoB
were simultaneously measured by immunoassay.
Statistical analysis
Data are presented as medians and interquartile ranges for
skewed variables. Unless otherwise indicated, values are
expressed as mean±SD or as percentages for categorical
variables. Comparisons between groups were performed
using Kruskal-Wallis test followed where relevant by
Mann-Whitney U test with adjustment for multiple com-
parisons (continuous variables) or the chi-square test
(categorical variables). Correlations between selected pairs
of variables were evaluated with the spearman correlation
and partial correlation with adjustment for age, gender
and other factors. The tHcy and tCys were divided into
quartiles for analysis. General linear model analysis was
performed to evaluate the relationship between tHcy, tCys
and the lipid profiles. In multiple logistic regressions, CAD
was considered as a dependent variable, with appropriate
adjustment for covariates.
The analyses were also performed for different combina-
tions of low (≤12 μmol/L), high (>12 μmol/L) tHcy or low
(<219.5 μmol/L), medium (219.5-284.1 μmol/L), high
(>284.1 μmol/L) tCys. Subjects with combinations of low
levels of tHcy and tCys served as the reference group. To
evaluate joint effect of tHcy and HDL or ApoA-I on the
risk of CAD, we also performed multiple logistic regres-
sions and adjustment for other covariates with different
combinations of low, high tHcy levels and high (>1.05
mmol/L), low (≤1.05 mmol/L) HDL cholesterol or high
(>1.17 mg/L), low (≤1.17 mg/L) ApoA-I. Subjects with
combinations of low levels of tHcy and high levels of HDL
cholesterol or ApoA-I served as the reference group. Two-
side P values below 0.05 were considered to indicate statis-
tical significance. All statistical analyses were performed
using SPSS 13.0 software (SPSS Inc., Chicago, Illinois).
Results
Clinical characteristics of subjects
Table 1 shows the study population characteristics stra-
tified by gender and presence or absence of CAD, 61%
of the study population was male, and 51% had CAD.
Mean age was 62.4 ± 12.5 years in the four subgroups.
Plasma triglycerides, HDL cholesterol, ApoA-I, fasting
plasma glucose were different in CAD cases relative to
control, as were plasma concentrations of tHcy and
creatinine. Plasma tCys levels were only increased in
CAD cases compared to control in males.
Relationship between lipid profiles and plasma tHcy, tCys
In spearman analysis (Table 2), plasma tHcy correlated
negatively with plasma HDL cholesterol and Apo A-I
levels (r = -0.148, P < 0.001 and r = -0.153, P < 0.001,
respectively). By using covariance analyses (ANCOVA),
the plasma HDL cholesterol and ApoA-I levels were
found stepwise decreasing from lowest quartile to highest
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confounders (all P < 0.001 for trend) (Table 3).
In an attempt to investigate a combination variable of
tHcy and tCys in relation to plasma HDL cholesterol
and ApoA-I levels (Figure 1), we found the lowest HDL
cholesterol and ApoA-I concentrations in subjects with
high tHcy and tCys. There were significant linear trend
decrease of HDL cholesterol and ApoA-I concentrations
in all of the 6 tHcy-tCys combination groups with and
without adjusted for age, gender and other confounders.
However, no significance was showed the changes of
HDL cholesterol and ApoA-I levels between the sub-
groups of low, medium, and high tCys levels in both
low and high tHcy levels.
Table 1 Demographic and clinical characteristics of the study population *
, †
Characteristics Men Women
Control
(n = 562)
CAD
(n = 693)
Control
(n = 443)
CAD
(n = 360)
Age, yrs
‡,§ 58.1 ± 14.6 63.7 ± 11.4
|| 61.4 ± 12.5 68.1 ± 10.2
||
BMI, kg/m
2 24.3 ± 4.32 24.7 ± 4.01 24.2 ± 4.33 24.6 ± 3.41
Smokers
‡,§ 186(33.1%) 253(36.5%)
|| 7(1.6%) 10(2.8%)
Hypertension
‡,§ 315(56.0%) 421(60.8%) 269(60.7%) 255(70.8%)
||
Positive family history 44(7.8%) 31(4.5%) 30(6.8%) 30(8.3%)
Total cholesterol, mmol/L
‡,§ 4.63 ± 1.03 4.57 ± 1.03 4.91 ± 1.06 5.08 ± 1.09
||
Triglycerides, mmol/L 1.82 ± 1.24 1.93 ± 1.27
|| 1.74 ± 1.13 1.95 ± 1.19
||
LDL cholesterol, mmol/L
§ 2.95 ± 0.90 2.92 ± 0.94 3.04 ± 0.94 3.16 ± 0.97
HDL cholesterol, mmol/L
‡,§ 1.06 ± 0.29 1.03 ± 0.34
|| 1.22 ± 0.30 1.18 ± 0.29
||
ApoA-I, mg/L
‡ 1.18 ± 0.44 1.11 ± 0.32
|| 1.31 ± 0.46 1.25 ± 0.26
||
ApoB, mg/L 0.77(0.64-0.88) 0.76(0.61-0.89) 0.78(0.64-0.90) 0.80(0.65-0.97)
LpA, mg/L 0.32(0.25-0.44) 0.34(0.24-0.47) 0.33(0.26-0.41) 0.34(0.26-0.45)
LDL cholesterol/ApoB ratio 3.87(3.46-4.23) 3.81(3.42-4.21) 3.88(3.45-4.29) 3.82(3.51-4.21)
Fasting plasma glucose, mmol/L 5.80 ± 2.23 6.19 ± 2.43
|| 5.98 ± 2.45 6.32 ± 2.81
||
Creatinine, μmol/L
‡ 87.5(73.0-104) 89.0(76.0-104)
|| 69.0(56.0-85.0) 71.0(58.0-89.0)
||
tHcy, μmol/L
‡,§ 13.8 ± 5.93 14.5 ± 6.13
|| 12.3 ± 5.53 12.9 ± 6.08
||
tCys, μmol/L 248.4 ± 46.3 255.8 ± 48.3
|| 254.2 ± 47.6 251.3 ± 45.5
* Values are mean ± SD, n (%), or median (interquartile range)
† BMI and plasma variables in the four groups were compared by Kruskal-Wallis test followed where relevant by Mann-Whitney U test with adjustment for
multiple comparisons. P < 0.0125(0.05/4) was considered significant.
‡ Significantly different in men compared to women in the no CAD group.
§ Significantly different in men compared to women in the CAD group.
|| Significantly different compared to no CAD group within the same gender.
Table 2 Correlation coefficients of plasma tHcy, tCys and other characteristics
tHcy (μmol/L) tCys (μmol/L)
r* Pr
† Pr * Pr
† P
BMI, kg/m
2 -0.021 0.684 0.038 0.467 -0.014 0.790 0.022 0.677
Total cholesterol, mmol/L -0.020 0.354 0.023 0.666 -0.008 0.707 0.033 0.533
Triglycerides, mmol/L -0.035 0.112 0.058 0.269 -0.004 0.866 0.045 0.386
LDL cholesterol, mmol/L -0.001 0.963 0.011 0.841 -0.010 0.648 0.018 0.728
HDL cholesterol, mmol/L -0.148 <0.001 -0.137 0.009 -0.003 0.891 0.022 0.669
ApoA-I, mg/L -0.153 <0.001 -0.135 0.010 0.029 0.189 0.018 0.735
ApoB, mg/L 0.002 0.946 0.002 0.965 -0.025 0.253 0.055 0.296
LpA, mg/L 0.021 0.331 -0.019 0.715 0.004 0.850 -0.053 0.316
LDL cholesterol/ApoB ratio -0.009 0.689 0.249 <0.001 0.026 0.232 0.042 0.427
Fasting plasma glucose, mmol/L -0.009 0.677 0.040 0.441 -0.016 0.476 -0.067 0.199
Creatinine, μmol/L 0.207 <0.001 0.228 <0.001 -0.011 0.629 0.026 0.616
* Correlation between selected paired variables was analysis with spearman correlation.
† Correlation between selected paired variables was analysis with partial correlation adjusted for age, gender, smoke, hypertension, positive family history and
coronary artery disease status.
Statistics for variables significantly associated with tHcy or tCys at P < 0.05 are shown in bold.
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After additional adjustment for the age, gender and
other potential confounders, plasma tCys showed no
apparent association, high concentration of tHcy seemed
to be associated with increased risk for CAD (OR: 1.34;
95% CI (1.04-1.74)) (Table 4). We investigated a combi-
nation variable of tHcy and tCys in relation to the CAD
risk (Figure 2A). Notably, the combinations of high tHcy
and low (OR: 1.528, 95% CI (1.161-2.011)), medium
(OR: 1.358, 95% CI (1.05-1.755)), or high tCys (OR:
1.696, 95% CI (1.301-2.211)) all had significantly
increased risk for CAD. However, after adjusted for age,
gender and other confounders, only the combination of
high tHcy and high tCys had a significantly increased
risk for CAD (OR: 1.499, 95% CI (1.137-1.976)).
Combined effect of plasma tHcy and HDL, ApoA-I on the
risk of CAD
In the correlation analysis, we found plasma tHcy were
associated negatively with plasma HDL cholesterol and
ApoA-I levels, further, we investigated a combination
variable of tHcy and HDL cholesterol or ApoA-I in rela-
tion to the CAD risk (Figure 2B). Interestingly, low
HDL cholesterol combined with low tHcy or high tHcy
all had increased risk for CAD (OR: 1.254, 95% CI
(1.114-1.565); OR: 1.332, 95% CI (1.093-1.624); respec-
tively) whereas combination of high HDL cholesterol
and high tHcy had no significant association with the
risk of CAD. In respect of combinations of tHcy and
ApoA-I, only the combination of high tHcy and high
ApoA-I had an increased risk for CAD (OR: 1.438, 95%
CI (1.170-1.768)).
Discussion
In this cross-sectional study, our results showed signifi-
cant negative relationship between plasma tHcy and
HDL cholesterol or ApoA-I levels, positive dose-response
relationship between plasma tHcy and the risk of CAD
was observed. Furthermore, we found the joint effects of
plasma tHcy and tCys decreased the plasma HDL choles-
terol and ApoA-I levels, and increased the risk of CAD.
In respect of joint effects of plasma tHcy and plasma
HDL cholesterol or ApoA-I, low HDL cholesterol com-
bined with both low and high tHcy increased the risk of
CAD whereas only combination of high ApoA-I and high
tHcy increased the risk of CAD.
Some reports showed a reduced expression of ApoA-I
and decreased HDL cholesterol levels were observed in
mice with genetically induced hyperhomocysteinemia. In
the methfr
+/- deficient mice model, homocysteine reduced
the expression of peroxisome proliferator-activated recep-
tor (PPARa) and decreased the ApoA-I promoter activity
and its protein levels [12]. In addition to its influence on
ApoA-I, hyperhomocysteinemia inhibited reverse choles-
terol transport by reducing circulating HDL via inhibiting
apoA-I protein synthesis and enhancing HDL cholesterol
clearance in the cbs
-/-apoe
-/- mice [11]. Moreover, homo-
cysteine associated with increased small size HDL3c
Table 3 Lipid profiles according to the quartiles of plasma tHcy and tCys levels *
Variable Q1 Q2 Q3 Q4 P for trend
tHcy (μmol/L) <9.1 9.1-12.3 12.4-16.5 >16.5
Total cholesterol, mmol/L 4.66(4.57-4.76) 4.81(4.72-4.89) 4.73(4.64-4.82) 4.79(4.69-4.88) 0.126
Triglycerides, mmol/L 1.89(1.77-2.02) 1.78(1.66-1.90) 1.93(1.81-2.05) 1.85(1.73-1.97) 0.383
LDL cholesterol, mmol/L 2.93(2.85-3.01) 3.03(2.95-3.11) 3.00(2.92-3.08) 3.04(2.96-3.12) 0.266
HDL cholesterol, mmol/L 1.15(1.14-1.17) 1.14(1.13-1.16) 1.08(1.07-1.10) 1.05(1.03-1.06) <0.001
ApoA-I, mg/L 1.26(1.24-1.28) 1.23(1.21-1.25) 1.19(1.17-1.21) 1.13(1.11-1.15) <0.001
ApoB, mg/L 0.76(0.74-0.79) 0.80(0.77-0.83) 0.82(0.79-0.85) 0.79(0.76-0.82) 0.094
LpA, mg/L 0.36(0.32-0.40) 0.46(0.42-0.49) 0.38(0.35-0.42) 0.40(0.37-0.44) 0.001
LDL cholesterol/ApoB ratio 3.87(3.64-4.10) 3.85(3.63-4.08) 4.07(3.85-4.30) 3.88(3.65-4.13) 0.481
tCys (μmol/L) <219.5 219.5-250.2 250.3-284.1 >284.1
Total cholesterol, mmol/L 4.73(4.64-4.82) 4.78(4.69-4.87) 4.76(4.67-4.85) 4.71(4.62-4.80) 0.675
Triglycerides, mmol/L 1.84(1.71-1.96) 1.93(1.81-2.05) 1.87(1.75-1.99) 1.83(1.70-1.94) 0.656
LDL cholesterol, mmol/L 2.98(2.91-3.07) 3.03(2.94-3.11) 3.02(2.94-3.10) 2.96(2.88-3.04) 0.685
HDL cholesterol, mmol/L 1.13(1.10-1.15) 1.08(1.05-1.11) 1.12(1.10-1.14) 1.10(1.07-1.13) 0.053
ApoA-I, mg/L 1.13(1.09-1.17) 1.14(1.10-1.18) 1.19(1.15-1.24) 1.12(1.08-1.17) 0.141
ApoB, mg/L 0.78(0.75-0.82) 0.80(0.77-0.83) 0.81(0.78-0.84) 0.79(0.76-0.82) 0.739
LpA, mg/L 0.44(0.40-0.47) 0.38(0.34-0.42) 0.41(0.38-0.45) 0.38(0.35-0.42) 0.073
LDL cholesterol/ApoB ratio 4.04(3.82-4.27) 3.80(3.58-4.03) 3.95(3.72-4.17) 3.89(3.67-4.12) 0.517
* Data are presented as mean (95% confidence interval). Analyses of covariance (ANCOVA) were performed using the general linear model approach after
adjustment for age, gender, smoke, hypertension, fasting plasma glucose, and creatinine.
P values are significant as shown in bold.
Q1 = quartile 1, Q2 = quartile 2, Q3 = quartile 3, Q4 = quartile 4
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ApoA-I and HDL and abnormal maturations of HDL
particles [18].
Previous studies showed plasma tCys is positively
related to cholesterol, diastolic blood pressure and BMI
in Hordaland homocysteine study [19,20], and positively
correlated with fasting LDL cholesterol and ApoB in the
COMAC cohort [8]. But in our present study, there was
no significant association between plasma tCys and
lipids levels. Because the blood samples in patients were
drawn after the disease episode, however, we cannot
rule out the possibility that tCys levels might be influ-
enced by the disease itself. There is also the possibility
that medication or change in lifestyle and dietary habits
might have influenced the levels of tCys in our popula-
tion [20]. In addition, several observations suggested
that the role of cysteine in hepatic synthesis of ApoB
may explain the epidemiology link of tCys and obesity
[20-22].
Homocysteine and cysteine have been considered as
risk factors of cardiovascular disease [8,23]. The studies
concerning homocysteine lowering vitamin therapy did
not mention the impact on cysteine levels [24,25]. We
excluded the subjects who used vitamin supplement
which might influence the plasma tHcy levels, but we
can not rule out the effect of the dietary changes of the
patients on the plasma tCys levels. It has been reported
that large variations of cysteine levels in plasma which
been observed in healthy subjects and this may be partly
related to food intake [26]. Underlying nutrient distur-
bances may be an important determinant of plasma
tCys levels. In addition, we did not select the health sub-
j e c t sa sc o n t r o l si no u rs t u d yp o p u l a t i o n ,t h i sm a yb ea
selective bias of no association between plasma tCys and
CAD.
Figure 1 Plasma HDL cholesterol and ApoA-I levels according
to the different combinations of tHcy and tCys levels. A. plasma
HDL cholesterol levels. B. plasma ApoA-I levels. Analyses of
covariance (ANCOVA) were performed using the general linear
model within different combinations of tHcy and tCys. Bars are
mean ± SEM, white bars are unadjusted, black bars are adjusted for
age, gender, smoke, hypertension, fasting plasma glucose, and
creatinine. Both P < 0.001 for trend, ns indicates no significant.
Table 4 Unadjusted and adjusted risk for CAD prevalence with increasing quartiles of tHcy and tCys levels
Q1 Q2 Q3 Q4 P for trend
tHcy (μmol/L) <9.1 9.1-12.3 12.4-16.5 >16.5
CAD 228(44.5%) 255(49.9%) 280(53.8%) 290(56.3%)
Unadjusted OR (95% CI) 1.0(referent) 1.24(0.97-1.58) 1.45(1.14-1.85) 1.61(1.26-2.05) P < 0.001
Adjusted OR* (95% CI) 1.0(referent) 1.08(0.83-1.39) 1.12(0.87-1.44) 1.35(1.04-1.74) P < 0.001
Adjusted OR
† (95% CI) 1.0(referent) 1.04(0.80-1.36) 1.14(0.88-1.47) 1.34(1.03-1.74) P < 0.001
tCys (μmol/L) <219.5 219.5-250.2 250.3-284.1 >284.1
CAD 259(50.6%) 261(50.5%) 260(50.4%) 273(53.2%)
Unadjusted OR (95% CI) 1.0(referent) 0.99(0.78-1.27) 0.98(0.77-1.26) 1.11(0.87-1.42) NS
Adjusted OR* (95% CI) 1.0(referent) 1.04(0.81-1.34) 1.05(0.82-1.35) 1.16(0.90-1.49) NS
Adjusted OR
† (95% CI) 1.0(referent) 1.02(0.79-1.32) 1.07(0.83-1.38) 1.17(0.91-1.52) NS
* Adjusted for age and gender.
† Adjusted for age, gender, smoke, hypertension, triglycerides, HDL, ApoA-I, fasting plasma glucose, creatinine.
CI = confidence interval, OR = odds ratio, Q1 = quartile 1, Q2 = quartile 2, Q3 = quartile 3, Q4 = quartile 4.
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ated for different combinations of tHcy and tCys concen-
trations. The subjects with high tHcys and high tCys
levels had the highest ORs for CAD with and without
adjustment for potential confounders. However, there
was no relation for CAD combined low tHcy levels with
medium and high tCys levels, this indicates that the
effects of high tCys on the risk of CAD are dependent on
the associated levels of tHcy [8]. Moreover, the subjects
with high tHcys and high tCys levels also had the lowest
HDL cholesterol and ApoA-I levels. This may suggest the
synergistic effects of tHcy and tCys decreased the plasma
HDL cholesterol and ApoA-I levels and increased the
risk of CAD [7,27].
Next, we analyzed the joint effects of tHcy and HDL
cholesterol or ApoA-I levels on the risk of CAD. Low
HDL cholesterol levels combined with both low and
high tHcy levels had significant ORs for CAD, it indi-
cates that low HDL cholesterol levels was independent
of plasma tHcy associated with the increased risk of
CAD. On the contrary, the subjects with high HDL cho-
lesterol levels and high tHcy levels had no significant
OR for CAD, this may be explained that the protective
effect of high HDL cholesterol levels could offset the
harmful effect of high tHcy levels on the risk of CAD.
On the other hand, the subjects with high ApoA-I levels
and high tHcy levels did not have protective effect but
increased the risk of CAD. Increased plasma tHcy levels
correlated negatively with decreased ApoA-I and HDL
cholesterol levels, and also positively with increased
small size HDL3c [18]. So the subjects with high tHcy
levels and high ApoA-I levels might have increased
plasma small size HDL3c levels. This suggested the sub-
jects with high tHcy levels which might impair the func-
tion of Apo-I and HDL and abnormal maturation of
HDL particles although in presence of high ApoA-I
levels would increase the risk of CAD.
Conclusion
our cross-sectional data showed that the plasma tHcy
rather than tCys was associated with decreased plasma
HDL cholesterol and ApoA-I levels and the increased
risk of CAD. Further, we found plasma tCys was depen-
dent on and increased the synergistic effect of plasma
tHcy. However, plasma HDL cholesterol was indepen-
dently and counteracted the effect of plasma tHcy. High
plasma tHcy was associated with increased risk of CAD
although in presence of high ApoA-I levels. Studies on
t h ej o i n te f f e c t so fp l a s m at H c ya n do t h e rr i s kf a c t o r s
on the risk of CAD are therefore underway.
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